Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV) reported stockholders’ equity of $3 million as of June 30, 2025, satisfying Nasdaq’s minimum requirement of $2.5 million needed to maintain its listing on the exchange. The clinical-stage pharmaceutical company, currently valued at $32.8 million in market capitalization, maintains a stronger cash position than debt on its balance sheet according to InvestingPro data.
The clinical-stage pharmaceutical company, which develops targeted radiotherapeutics for central nervous system cancers, had previously fallen below the threshold based on its March 31, 2025 financial position, prompting Nasdaq to issue a delisting determination on June 3, 2025.
Plus Therapeutics requested a hearing before the Nasdaq Hearings Panel, which was held on July 15, 2025. The panel subsequently granted the company an extension to demonstrate compliance with the equity requirement.
The company confirmed its compliance with the listing standard in its quarterly financial report filed on August 14, 2025, and now awaits official confirmation from Nasdaq.
Plus Therapeutics has been operating under a Mandatory Panel Monitor through March 6, 2026, specifically regarding the equity rule compliance issue.
Headquartered in Houston, the company focuses on developing treatments for difficult-to-treat cancers of the central nervous system, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma.
The information in this article is based on a company press release statement.
In other recent news, Plus Therapeutics, Inc. announced positive results from a retrospective analysis of its CNSide Cerebrospinal Fluid Assay Platform, which was presented at the 2025 Society for Neuro-Oncology/American Society of Clinical Oncology CNS Metastases Conference. The study found that cerebrospinal fluid tumor cells were detected in 67% of patients using this platform. Additionally, the company has received an extension from a Nasdaq Hearings Panel to regain compliance with Nasdaq Capital Market listing standards after reporting a stockholders’ deficit of $23.6 million as of March 31, 2025.
Plus Therapeutics also announced that its subsidiary, CNSide Diagnostics, will launch its cerebrospinal fluid assay platform in Texas in August 2025, targeting major cancer centers in the state. Furthermore, the company received a $1.6 million advance from the Cancer Prevention and Research Institute of Texas as part of a previously awarded $17.6 million grant, with expectations of receiving approximately $6 million more over the next year. In another development, Plus Therapeutics began treating patients in the ReSPECT-LM dose optimization trial for REYOBIQ, aiming to identify optimal dosing regimens for leptomeningeal metastases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.